Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Gnetin C sensitizes darolutamide-resistant prostate oncology research models cells by [PMID: 40393106] Laboratory literature summary: Gnetin C sensitizes darolutamide-resistant prostate oncology research models cells by targeting NAD(+) and energy metabolism
Related BPC-157 Research Compounds Researchers working with the BPC-157 TB-500 blend may also be interested in these related compounds from our catalogue: BPC-157 5mg standalone BPC-157 for isolated single-compound research protocols BPC-157 10mg higher dosage standalone vial for extended research cycles BPC-157 15mg maximum standalone dosage for high-concentration laboratory studies BPC-157 + TB-500 20mg Blend double-strength version of this formulation for extended protocols BPC-157 + TB-500 + GHK-Cu 30mg Glow Blend triple-compound blend adding copper peptide for extracellular matrix research All compounds are independently tested by Janoshik Analytical and supplied with batch-specific COA documentation
25 The dosing schedule was 1000 g daily for 7 days, then 1000 g once per week for 1 month, then 1 1000 g injection monthly for 6 months
Mechanistic Focus in Research Within experimental laboratory settings, NAD+ is commonly studied in relation to metabolic and biochemical signalling pathways
